A Long-term Follow-up Study of Patients Who Received VOR33

Vor Biopharma

Status: Enrolling

Conditions: Leukemia, Myeloid, Acute

Treatments: Genetic: VOR33

Study type: Observational

Funder types: Industry

Identifiers

NCT05309733

VBP201

Details and patient eligibility

About

VOR33 long-term follow-up (LTFU) study

Full description

VBP201 study is the VOR33 long-term follow-up (LTFU) study focusing on assessing long term safety and efficacy of VOR33. This study may last up to 15 years (counted from the date of VOR33 infusion completion). All patients who have participated in a study involving the drug product VOR33 and have completed the applicable study or prematurely discontinued, but have at least received the VOR33 infusion, will be asked to participate in the LTFU study.

Enrollment: 36 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• A patient is included in this study if he/she:

  1. Has received any part of or all of a VOR33 infusion

Exclusion criteria

• There are no exclusion criteria.

Trial design

36 participants in 1 patient group

Observational Cohort 1

Description:

All patients who have received any part of or all of a VOR33 genome-edited hematopoietic stem and progenitor cell therapy product.

Treatment:

Genetic: VOR33